BRPI0814688A2 - composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica - Google Patents

composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica

Info

Publication number: BRPI0814688A2
Authority: BR; Brazil
Prior art keywords: compound; warm; producing; methods; pharmaceutical composition
Prior art date: 2007-07-09

Application number

BRPI0814688A

Other languages

English (en)

Inventor

Gordon Pike Kurt

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-09

Filing date

2008-07-08

Publication date

2017-06-06

2008-07-08 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2017-06-06 Publication of BRPI0814688A2 publication Critical patent/BRPI0814688A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0814688A 2007-07-09 2008-07-08 composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica BRPI0814688A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94853907P	2007-07-09	2007-07-09
PCT/GB2008/050548 WO2009007750A1 (en)	2007-07-09	2008-07-08	Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k

Publications (1)

Publication Number	Publication Date
BRPI0814688A2 true BRPI0814688A2 (pt)	2017-06-06

Family

ID=39791229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814688A BRPI0814688A2 (pt)	2007-07-09	2008-07-08	composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica

Country Status (21)

Country	Link
US (1)	US8138183B2 (pt)
EP (1)	EP2176238B1 (pt)
JP (1)	JP5508260B2 (pt)
KR (1)	KR20100042280A (pt)
CN (1)	CN101809002B (pt)
AR (1)	AR070079A1 (pt)
AT (1)	ATE554075T1 (pt)
AU (1)	AU2008273891B2 (pt)
BR (1)	BRPI0814688A2 (pt)
CA (1)	CA2692720A1 (pt)
CL (1)	CL2008003940A1 (pt)
CO (1)	CO6251364A2 (pt)
CR (1)	CR11200A (pt)
DO (1)	DOP2010000012A (pt)
EA (1)	EA018708B1 (pt)
EC (1)	ECSP109935A (pt)
ES (1)	ES2385692T3 (pt)
NI (1)	NI201000002A (pt)
PE (1)	PE20100138A1 (pt)
WO (1)	WO2009007750A1 (pt)
ZA (1)	ZA200909224B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101801962A (zh) *	2007-07-09	2010-08-11	阿斯利康(瑞典)有限公司	用于治疗增殖疾病的三取代嘧啶衍生物
JP5599783B2 (ja)	2008-05-30	2014-10-01	アムジエン・インコーポレーテツド	Ｐｉ３キナーゼの阻害薬
WO2010103094A1 (en)	2009-03-13	2010-09-16	Cellzome Limited	PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UY32582A (es)	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5680638B2 (ja)	2009-07-02	2015-03-04	サノフイ	新規な（６−オキソ−１，６−ジヒドロピリミジン−２−イル）アミド誘導体、この調製およびａｋｔ（ｐｋｂ）リン酸化インヒビターとしてのこの医薬的な使用
AR077628A1 (es)	2009-07-02	2011-09-14	Sanofi Aventis	Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
KR20120115237A (ko)	2009-10-30	2012-10-17	어리어드 파마슈티칼스, 인코포레이티드	암 치료 방법 및 조성물
SG183155A1 (en)	2010-02-03	2012-09-27	Signal Pharm Llc	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
ES2535116T3 (es)	2010-03-04	2015-05-05	Cellzome Limited	Derivados de urea sustituida con morfolino como inhibidores de mtor
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
HRP20170119T1 (hr)	2010-12-28	2017-03-24	Sanofi	Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
JP2014510122A (ja)	2011-04-04	2014-04-24	セルゾームリミテッド	ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
KR20220002713A (ko)	2011-04-29	2022-01-06	셀렉타 바이오사이언시즈, 인크.	치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체
CA2843887A1 (en)	2011-08-03	2013-02-07	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for lkb1 status
KR20140070616A (ko)	2011-09-21	2014-06-10	셀좀 리미티드	Mtor 저해제로서의 모르폴리노 치환된 우레아 또는 카바메이트 유도체
JP6093770B2 (ja)	2011-09-27	2017-03-08	アムジエン・インコーポレーテツド	癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
WO2013050508A1 (en)	2011-10-07	2013-04-11	Cellzome Limited	Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
JP6148729B2 (ja)	2012-07-04	2017-06-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	共有結合している抗原−抗体結合体
FR2994572B1 (fr) *	2012-08-17	2015-04-17	Centre Nat Rech Scient	Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014219075C1 (en) *	2013-02-19	2018-09-06	Amgen Inc.	Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014236812B2 (en)	2013-03-14	2018-03-01	Amgen Inc.	Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
BR112015026257B1 (pt)	2013-04-17	2022-12-20	Signal Pharmaceuticals, Llc	Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
TWI604843B (zh)	2013-04-17	2017-11-11	標誌製藥公司	藉二氫吡并吡治療癌症
KR102221029B1 (ko)	2013-04-17	2021-02-26	시그날 파마소티칼 엘엘씨	디하이드로피라지노-피라진을 사용한 암의 치료
HK1221168A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治療癌症的包括tor激酶抑制劑和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的組合療法
NZ631082A (en)	2013-04-17	2017-06-30	Signal Pharm Llc	Methods for treating cancer using tor kinase inhibitor combination therapy
JP2016516815A (ja)	2013-04-17	2016-06-09	シグナルファーマシューティカルズ，エルエルシー	１−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
WO2014172436A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP2016517889A (ja)	2013-05-03	2016-06-20	セレクタバイオサイエンシーズインコーポレーテッドＳｅｌｅｃｔａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子
US9604939B2 (en)	2013-05-29	2017-03-28	Signal Pharmaceuticals, Llc	Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
JOP20200296A1 (ar)	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
CN111228509A (zh)	2014-01-03	2020-06-05	豪夫迈·罗氏有限公司	双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
WO2015160880A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
KR20170026362A (ko) *	2014-06-26	2017-03-08	에프. 호프만-라 로슈 아게	항-ｂｒｄｕ 항체 및 사용 방법
DK3177612T3 (da)	2014-08-04	2022-05-16	Nuevolution As	Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme
BR112017001601A2 (pt)	2014-09-07	2017-11-21	Selecta Biosciences Inc	métodos e composições para atenuar as respostas imunes do vetor de transferência antiviral de modulação da expressão genética
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
CN110612122A (zh)	2017-03-11	2019-12-24	西莱克塔生物科技公司	与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
WO2018218197A2 (en)	2017-05-26	2018-11-29	Board Of Regents, The University Of Texas System	Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
KR102795129B1 (ko)	2017-06-22	2025-04-15	셀진 코포레이션	B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
ES2974334T3 (es)	2017-07-13	2024-06-26	Univ Texas	Inhibidores heterocíclicos de ATR cinasa
CN111886224B (zh)	2017-08-17	2024-07-23	德州大学系统董事会	Atr激酶的杂环抑制剂
CN112218631B (zh)	2018-03-16	2023-12-22	德州大学系统董事会	Atr激酶的杂环抑制剂
JP2021098692A (ja)	2019-12-20	2021-07-01	ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎＡ／Ｓ	核内受容体に対して活性の化合物
JP2023519603A (ja)	2020-03-31	2023-05-11	ヌエヴォリューション・アクティーゼルスカブ	核内受容体に対して活性な化合物
WO2021198956A1 (en)	2020-03-31	2021-10-07	Nuevolution A/S	Compounds active towards nuclear receptors
CN111646985A (zh) *	2020-06-01	2020-09-11	江苏集萃分子工程研究院有限公司	一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3922735A1 (de)	1989-07-11	1991-01-24	Hoechst Ag	Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
ATE503743T1 (de)	2000-04-27	2011-04-15	Astellas Pharma Inc	Kondensierte heteroarylderivate
JP3810017B2 (ja) *	2000-04-27	2006-08-16	アステラス製薬株式会社	縮合ヘテロアリール誘導体
CN1473156A (zh)	2000-11-10	2004-02-04	-	嘧啶衍生物及其作为神经肽y受体配体的用途
EA013811B1 (ru)	2002-11-21	2010-08-30	Новартис Вэксинес Энд Дайэгностикс, Инк.	2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
EP1626725A4 (en)	2003-05-29	2006-06-14	Synta Pharmaceuticals Corp	Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
GB0415367D0 (en) *	2004-07-09	2004-08-11	Astrazeneca Ab	Pyrimidine derivatives
GB0415364D0 (en) *	2004-07-09	2004-08-11	Astrazeneca Ab	Pyrimidine derivatives
GB0415365D0 (en) *	2004-07-09	2004-08-11	Astrazeneca Ab	Pyrimidine derivatives
US7772271B2 (en)	2004-07-14	2010-08-10	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
WO2007084413A2 (en)	2004-07-14	2007-07-26	Ptc Therapeutics, Inc.	Methods for treating hepatitis c
JP2008519850A (ja)	2004-11-10	2008-06-12	シンタファーマシューティカルズコーポレーション	Ｉｌ−１２調節化合物
WO2006124874A2 (en)	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
TW200720256A (en)	2005-05-13	2007-06-01	Synta Pharmaceuticals Corp	IL-12 modulatory compounds
ES2473341T3 (es)	2005-05-20	2014-07-04	Methylgene Inc	Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
DE102005024494A1 (de)	2005-05-27	2006-11-30	Bayer Healthcare Ag	Verwendung von Cyanopyrimidinen
KR20080015475A (ko)	2005-07-01	2008-02-19	아이알엠 엘엘씨	단백질 키나제 억제제로서의 피리미딘-치환 벤즈이미다졸유도체
WO2007013691A1 (ja)	2005-07-29	2007-02-01	Takeda Pharmaceutical Company Limited	スピロ環化合物
US20070049603A1 (en)	2005-09-01	2007-03-01	Greg Miknis	Raf inhibitor compounds and methods of use thereof
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
JP4531027B2 (ja)	2005-09-29	2010-08-25	田辺三菱製薬株式会社	医薬組成物
CA2623032A1 (en)	2005-09-30	2007-04-12	Vertex Pharmaceuticals Incorporated	Deazapurines useful as inhibitors of janus kinases
KR101487027B1 (ko)	2005-09-30	2015-01-28	미카나 테라퓨틱스, 인크.	치환된 피라졸 화합물
GB0520657D0 (en)	2005-10-11	2005-11-16	Ludwig Inst Cancer Res	Pharmaceutical compounds
GB2431156A (en) *	2005-10-11	2007-04-18	Piramed Ltd	1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
HRP20120824T1 (hr)	2005-10-28	2012-11-30	Astrazeneca Ab	Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma
CA2636314A1 (en)	2005-11-29	2007-06-07	Toray Industries, Inc.	Arylmethylene urea derivative and use thereof
GB0525081D0 (en)	2005-12-09	2006-01-18	Astrazeneca Ab	Pyrimidine derivatives
GB0525083D0 (en) *	2005-12-09	2006-01-18	Astrazeneca Ab	Pyrimidine derivatives
GB0525080D0 (en)	2005-12-09	2006-01-18	Astrazeneca Ab	Pyrimidine derivatives
NL2000323C2 (nl)	2005-12-20	2007-11-20	Pfizer Ltd	Pyrimidine-derivaten.
AU2007204208A1 (en)	2006-01-11	2007-07-19	Astrazeneca Ab	Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
EA200870217A1 (ru)	2006-01-30	2009-02-27	Экселиксис, Инк.	4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2007105023A1 (en)	2006-03-15	2007-09-20	Csir	Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja)	2006-03-17	2013-07-24	田辺三菱製薬株式会社	ベンゼン誘導体
US8044068B2 (en)	2006-04-04	2011-10-25	Taisho Pharmaceutical Co., Ltd	Aminopyrrolidine compound
AU2007240496A1 (en)	2006-04-19	2007-11-01	Novartis Ag	Indazole compounds and methods for inhibition of CDC7
WO2007126043A1 (ja)	2006-04-27	2007-11-08	Mitsubishi Tanabe Pharma Corporation	チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en)	2006-06-05	2006-07-12	Merck Sharp & Dohme	Therapeutic treatment
CA2656290A1 (en)	2006-07-05	2008-01-10	Exelixis, Inc.	Methods of using igf1r and abl kinase modulators
EP2057140B1 (en)	2006-08-24	2012-08-08	AstraZeneca AB	Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010501537A (ja) *	2006-08-24	2010-01-21	アストラゼネカアクチボラグ	増殖性障害の治療に有用なモルホリノピリミジン誘導体
US20080234262A1 (en) *	2007-03-21	2008-09-25	Wyeth	Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
JP2010523637A (ja)	2007-04-12	2010-07-15	エフ．ホフマン−ラロシュアーゲー	医薬化合物
CN101801963A (zh)	2007-07-09	2010-08-11	阿斯利康(瑞典)有限公司	用于治疗增殖性疾病的三取代的嘧啶衍生物

2008
- 2008-07-08 AU AU2008273891A patent/AU2008273891B2/en not_active Ceased
- 2008-07-08 ES ES08776183T patent/ES2385692T3/es active Active
- 2008-07-08 WO PCT/GB2008/050548 patent/WO2009007750A1/en active Application Filing
- 2008-07-08 AT AT08776183T patent/ATE554075T1/de active
- 2008-07-08 EA EA201000091A patent/EA018708B1/ru not_active IP Right Cessation
- 2008-07-08 KR KR1020107002942A patent/KR20100042280A/ko not_active Ceased
- 2008-07-08 CN CN2008801062258A patent/CN101809002B/zh not_active Expired - Fee Related
- 2008-07-08 CA CA 2692720 patent/CA2692720A1/en not_active Abandoned
- 2008-07-08 JP JP2010515602A patent/JP5508260B2/ja not_active Expired - Fee Related
- 2008-07-08 EP EP08776183A patent/EP2176238B1/en active Active
- 2008-07-08 BR BRPI0814688A patent/BRPI0814688A2/pt not_active IP Right Cessation
- 2008-07-08 US US12/668,056 patent/US8138183B2/en not_active Expired - Fee Related
- 2008-12-19 PE PE2008002157A patent/PE20100138A1/es not_active Application Discontinuation
- 2008-12-30 CL CL2008003940A patent/CL2008003940A1/es unknown
- 2008-12-30 AR ARP080105784A patent/AR070079A1/es unknown
2009
- 2009-12-23 ZA ZA2009/09224A patent/ZA200909224B/en unknown
2010
- 2010-01-08 DO DO2010000012A patent/DOP2010000012A/es unknown
- 2010-01-08 CR CR11200A patent/CR11200A/es not_active Application Discontinuation
- 2010-01-08 NI NI201000002A patent/NI201000002A/es unknown
- 2010-02-03 EC EC2010009935A patent/ECSP109935A/es unknown
- 2010-02-09 CO CO10014081A patent/CO6251364A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA201000091A1 (ru)	2010-06-30
CN101809002B (zh)	2013-03-27
WO2009007750A1 (en)	2009-01-15
CA2692720A1 (en)	2009-01-15
ECSP109935A (es)	2010-03-31
AR070079A1 (es)	2010-03-10
DOP2010000012A (es)	2010-01-31
CR11200A (es)	2010-06-17
PE20100138A1 (es)	2010-03-20
NI201000002A (es)	2010-10-12
US8138183B2 (en)	2012-03-20
ES2385692T3 (es)	2012-07-30
EA018708B1 (ru)	2013-10-30
CN101809002A (zh)	2010-08-18
KR20100042280A (ko)	2010-04-23
CO6251364A2 (es)	2011-02-21
US20100249131A1 (en)	2010-09-30
ATE554075T1 (de)	2012-05-15
EP2176238A1 (en)	2010-04-21
HK1142906A1 (en)	2010-12-17
JP5508260B2 (ja)	2014-05-28
EP2176238B1 (en)	2012-04-18
AU2008273891A1 (en)	2009-01-15
CL2008003940A1 (es)	2010-09-24
ZA200909224B (en)	2011-05-25
JP2010533160A (ja)	2010-10-21
AU2008273891B2 (en)	2012-01-12

Publication	Publication Date	Title
BRPI0814688A2 (pt)	2017-06-06	composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0820474A2 (pt)	2017-05-23	método de tratamento de uma doença, uso de composto, e, composto
BRPI0821274A2 (pt)	2017-06-13	composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0914233A2 (pt)	2015-11-03	composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
BRPI0817917A2 (pt)	2015-04-07	Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI0808034A2 (pt)	2014-06-17	Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0815057A2 (pt)	2015-07-28	Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0811275A2 (pt)	2014-12-23	Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.

Legal Events

Date	Code	Title	Description
2017-06-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-26	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]